Waiver of Parental Permission
Waiver of Parental permission is permitted under 45 CFR 46.408(c) when it is not a reasonable requirement to protect subjects. This waiver is usually but not always limited to minimal risk research, such as surveys, interviews or focus groups. Research about sexuality, drug use, teen driving habits or other topics of importance to adolescents may not be possible without a waiver. The parents of these teens may not be accessible and therefore, may not be a reasonable requirement.
The FDA's regulations do not have a comparable waiver of parental permission to match 45 CFR 46.408(c). The FDA's regulations do permit waiver of consent but only under the narrow exception for emergency research meeting the requirements of 21 CFR 50.24. In addition, under their Guidance issued in July 2017, the FDA also indicated that it would use regulatory discretion and allow IRB's to waive the requirements for consent for "minimal risk" clinical investigations.
Waiver or alteration of consent
- 46.408(c) requires the substitution of another mechanism to protect the subjects. This could be as simple as requiring assent of teenagers (typically 14 years or older) who are mature enough to fully comprehend the research activities. It could also involve appointing an advocate who provides permission for the child.
- If research will be performed in the schools, it may be possible to send information home to parents that allows them to opt out. Then the teens may assent for their own participation provided their parent has not opted out.
- The IRB requires the investigator to make a compelling and persuasive argument for why parental permission is not a necessary condition for proceeding with the research.